In August 2025, Paul Shapiro’s Better Meat Co. raised $31m and told the trade press it would sell its mycoprotein, Rhiza, at prices below US commodity ground beef within 2026. Thirteen months later the company has a new name, BMC Ingredients, no facility beyond the 9,000-litre demonstration plant it started with, and a price-parity claim that has been quietly re-pointed at a factory in Asia due Q2 2027.
This is not a story about a company running out of money. Unlike the financing gap stalling Liberation Bioindustries’ Richmond plant, BMC Ingredients raised the capital it asked for, has FDA and now Health Canada clearance in hand, and says demand exceeds what it can make. The constraint here is that the capacity was never built, and the date attached to building it has moved by at least a year without anyone at the company calling it a delay.
The record, assembled
Every date below comes from a source we fetched and read, including the FDA’s own GRAS notice record.
| Date | Source | What was stated |
|---|---|---|
| 9 July 2024 | FDA GRAS Notice Inventory, GRN 1117 | FDA has “no questions” on mycelial biomass from Neurospora crassa as a protein ingredient up to 90% in meat, poultry, seafood and their alternatives |
| 27–28 August 2024 | FoodNavigator, Food Dive | $1.4m US Department of Defense grant awarded to commercialise Rhiza |
| 19 March 2025 | Protein Production Technology International | Five signed letters of intent, the largest for 30 dry tons of Rhiza monthly (90 tons hydrated) from an unnamed South American meat producer; combined LOIs projected at $13m/year; company cites a “150,000-litre” facility planned through a contract manufacturer |
| 19 August 2025 | AgFunderNews | $31m Series A closes (total raised to date: $43.1m); target capacity described as 90,000 litres, a stated “10x” increase from the 9,000-litre Sacramento plant |
| 26 August 2025 | FoodNavigator | Company states it will sell “at prices lower than US commodity ground beef within 2026” |
| 7 July 2026 | Green Queen | Rebrand to BMC Ingredients; Sacramento plant “completely maxed out,” several purchase orders needing “double-digit tons” turned down; new commercial facility announced in Asia, 100 dry tonnes monthly, opening Q2 2027; price parity now stated as contingent on “once fully commercialised in our new facility” |
| 28 July 2026 (updated 25 August 2026) | Green Queen | Health Canada issues a letter of no objection for Rhiza; CEO states the company intends to be “producing large-scale commercial volumes of Rhiza mycoprotein starting within Q2 2027, including shipping to Canada” |
Two things stand out. First, no source anywhere in this record uses the word “delay,” “slip” or “revised.” The 2026 pricing target simply stops appearing after July 2025 and a 2027 target appears in its place, attached to a facility that did not exist in any of the company’s public statements before July 2026. Second, the unit of measurement for capacity changes three times — 150,000 litres (March 2025), 90,000 litres (August 2025), 100 dry tonnes per month (July 2026) — and litres of fermenter volume cannot be converted to tonnes of output without titre, cycle time and yield figures that BMC Ingredients has not published, the same measurement gap we found in mycoprotein capacity figures quoted without a stated basis. A reader cannot tell whether the Asian facility is larger or smaller than the 90,000-litre plant once discussed, because the two figures are not in the same units.
Practical consequence. Treat “capacity” claims from this company, and this sector generally, as unusable for comparison unless both a volume and a product-tonnage figure are given for the same date. Track the tonnage figure alone across time; it is the only unit that has appeared consistently enough to be comparable — 30 dry tons/month in one buyer’s LOI (March 2025) against 100 dry tonnes/month of total planned output (July 2026).
What “completely maxed out” actually discloses
The July 2026 rebrand announcement is more informative about capacity than either of the funding releases that preceded it, because it is the first time the company describes hitting a wall rather than describing a plan. BMC Ingredients says its Sacramento demonstration plant — the same 9,000-litre facility referenced in every release since 2024 — is booked through the rest of 2026, and that it has turned down orders requiring “double-digit tons,” i.e., in the range of roughly 10–99 tons of product, a threshold well below the 30 dry tons a month a single named buyer’s letter of intent already implied in March 2025.
Read against the August 2025 raise, this means the $31m round did not fund a facility that ever became operational under Better Meat Co.’s own name. Fourteen months elapsed between “we will scale to 90,000 litres” and “we are opening a 100-tonne-a-month facility in Asia” — and the intervening record contains no announcement of groundbreaking, siting, or construction for either the domestic expansion implied in August 2025 or the Asian facility named in July 2026. Either the domestic plan was abandoned in favour of the Asian site, or the two were never the same project — the public record does not say which, and we did not find a source that addresses the change directly.
Practical consequence. A signed LOI at this company’s current scale is a claim on future capacity that does not yet exist. A counterparty underwriting supply against a named tonnage figure from BMC Ingredients should ask for a construction start date and a site, not a production percentage — the same test we set out for Liberation Bioindustries’ “under contract” capacity language.
The GRAS letter didn’t need to wait for the plant. Health Canada didn’t either
BMC Ingredients’ regulatory position has moved in a straight line while its production position has not. GRN 1117 closed in July 2024, more than two years before any commercial-scale facility. Health Canada’s letter of no objection followed in July 2026, again ahead of any operating plant that could ship into Canada. Both clearances were obtained on the strength of R&D-scale data and safety dossiers, not commercial-scale manufacturing evidence, which is exactly how the GRAS and Canadian novel-food-adjacent pathways are designed to work.
This is the inverse of the pattern in Believer Meats, where approval was secured, capital was raised, and the company still shut down because production cost, not regulatory status, was the binding constraint. Here the regulatory record is not the binding constraint either — the FDA and Health Canada have both said yes — but production capacity is, and it has been the same 9,000-litre plant since before the company’s first public disclosure in 2024.
Practical consequence. For mycoprotein specifically, a fermentation-derived ingredient with a “no questions” GRAS letter, do not treat the clearance as a leading indicator of a launch date. It is necessary and, on this record, arrives years ahead of the capacity that would let a company act on it.
The counter-argument
The charitable reading has real support. Turning down “double-digit ton” orders because the existing plant is booked through year-end is a description of a company managing demand it cannot yet meet, not one failing to find demand — the opposite problem from most of what this publication covers, where the failure mode is capacity nobody wants. A company adding a second geography (Health Canada), a second product category (the rebrand explicitly cites dairy alternatives, smoothies, bars, pasta, baked goods and “longevity” applications), and a confirmed customer (Oshi, a plant-based salmon company named in the July 2026 release) in the same year it says its only plant is oversubscribed is consistent with a company scaling faster than its infrastructure, not one struggling to survive it.
It is also true that “beat beef by 2026” was always a target tied to a facility that, on the public record, only started to take a concrete shape — a location, a monthly tonnage, an opening quarter — in July 2026. A target attached to an unbuilt facility moving once that facility’s real parameters become known is a normal feature of early-stage manufacturing planning, not evidence of trouble. CEO Paul Shapiro has been candid elsewhere about the sector’s difficulty: in the same August 2025 raise, he described the odds of survival in alt-protein manufacturing as comparable to “being a player in Squid Game,” while noting the company has never conducted layoffs through a Silicon Valley Bank collapse and a multi-year litigation.
The honest position is that the public record supports both readings and does not distinguish between them: a capital-efficient company sequencing a harder facility decision correctly, and a company whose 2026 commercial promise quietly became a 2027 promise with no acknowledgment that anything moved.
What we could not establish
- Why the plan changed from a domestic 90,000-litre expansion (August 2025) to a 100-dry-tonne-per-month Asian facility (July 2026). No source we fetched addresses whether these were ever the same project, sequential projects, or parallel tracks where one was quietly dropped.
- The identity of the South American buyer behind the 30-dry-ton-a-month letter of intent, or whether that LOI has since converted to a binding offtake agreement, been renegotiated, or lapsed.
- Current status of the “five signed LOIs” disclosed in March 2025 and their combined $13m/year projection — no later source updates this figure.
- A construction start date, site, or capital cost for the Asian facility. The July 2026 release names a monthly tonnage and an opening quarter; it does not name a country, a builder, or a total investment figure.
- Whether the $1.4m DoD grant or any Series A proceeds were applied toward the Asian facility, as opposed to Sacramento operations or R&D. No source itemises use of funds at that level.
- The exact close date of the Health Canada review — the letter of no objection is dated in the release only as arriving in the week of the 28 July 2026 article; we have not seen the underlying regulatory filing date.
What to watch
- A named site or groundbreaking announcement for the Q2 2027 Asian facility. Until one exists, “Q2 2027” carries the same evidentiary weight the 2026 target carried in August 2025.
- Whether the “beat beef” pricing claim reappears with a specific figure. Every version of this claim so far has been comparative (“lower than,” “cheaper than”) rather than a stated cost per kilogram or per pound.
- Disclosure of a binding offtake agreement, as distinct from a letter of intent, with the South American buyer or any other named counterparty.
- A tonnage figure for the existing Sacramento plant’s actual annual output, which would let the “maxed out” claim be checked against a number rather than taken on description alone.
We will update this article rather than publish a second one if BMC Ingredients names a site for the Asian facility or the price-parity claim resolves either way.